|Articles|July 1, 2004
Consider the complete picture of a therapy's efficacy
I am writing to add clarification to an article about dry eye that underreports the clinical efficacy and symptom improvement period for cyclosporine (CsA) ophthalmic emulsion 0.05% (Restasis, Allergan) ("Dry eye: what's in the pipeline?" by Joseph Mussoline, MD, Ophthalmology Times, March 15, 2004, Pages 18 to 19).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
First patient treated in ViaLase’s IDE trial
2
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
3
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
4
FDA grants IDE approval to EyeYon Medical for its US clinical study of EndoArt
5











































.png)


